Patients’ medication regimen and medication-taking behaviour should be re-evaluated regularly (every 3–6 months) and adjusted as needed to incorporate patient-specific factors that may impact the choice of treatment.8 Furthermore, based on current guidelines, SGLT2 inhibitors should also be considered to improve HF outcomes in patients without T2D when clinically appropriate. The gene discussed is SLC5A2; the disease is hydrops fetalis.